12:00 AM
 | 
Apr 07, 2008
 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch

Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 12 mos ended 12/31
1/15/08 NitroMed (NASDAQ:NTMD) 89% to 10 $31.4 0.96 12/31/07 $32.8
Exploring strategic alternatives; discontinuing sales and promotional activities for BiDil, although the fixed-dose combination of hydralazine hydrochloride and disosorbide dinitrate will remain on the market to treat heart failure in black patients
1/21/08 Curalogic (CSE:CUR) 50% to 7 $64.6 1.58 12/31/07 $40.8
Aiming to secure a deal this year for new development projects after its ragweed allergy vaccine failed a Phase III trial
1/29/08 Neose (NASDAQ:NTEC) 40% to ~30 $19.3 0.52 12/31/07 $37.0
Focusing on GlycoPEG-GCSF, a pegylated version of G-CSF, and also on its collaboration with Novo Nordisk (CSE:NVO; NYSE:NVO) to develop next-generation versions of Factors VIIa, VIII and IX
2/1/08 Vyteris (OTCBB:VYHN) 62% to ~20 $6.2 0.12 9/30/07 $37.4 (A)
Focusing on the development of its Smart Patch transdermal peptide delivery system
2/6/08 Neurogen (NASDAQ:NRGN) 48% to 75 $42.6 0.73 12/31/07

Read the full 1028 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >